Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My shares are smelling better and better. Thanks Jacob.
Thanks Micro for your great DD, as usual.
Looks like a Christmas tree! Go CWRN!
Wow Microcaps! Are you saying we are shipping again?!!!
It would probably be difficult to pass laws against it given the vested interests, but it is good to educate investors on how these scumbags really operate.
Do a search on the name of the filing lawfirm + shareholder suits. Look at the hundreds of suits they file. It's a nuisance lawsuit factory.
The lawfirms that do this scan stockcharts all day for big drops, and then send out pre-packaged suits and press releases to try to get out-of-court settlements.
These cases drain cash from struggling companies and make it hard for them to make the needed investments to recover. DCTH needs to be prepping for FDA in the fall, not paying extortion. If they do pay, every sleazebag attorney will be on their door.
They are sharks feasting on both the wounded company AND the shareholders. They are not your friends.
Liveblog of AVEO/DCTH ODAC
http://www.thestreet.com/story/11911563/1/aveo-delcath-fda-panel-live-blog.html
By AF - seems to be staying neutral.
No I was just remarking on the time posted in the announcements window of IHUB.
What exactly does stock price smell like? I have tried sniffing my computer screen at both .0006 and .0007 and it smells exactly the same.
Mar 21 announcement was after 7pm
The Street is not news. AF is a shorter.
Too few people are reading the documents. Conclusion - positive risk/benefit. Remember, 10% shares are short. Once they start to cover, this may turn fast.
DCTH briefing docs are out. A lot of people are spinning the information one way or another - do your own DD today.
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm341089.htm
11.3. Benefit-Risk Conclusions
There is no standard of care and no approved therapy for patients with unresectable, hepatic
metastases from ocular melanoma. Thus, there is an unmet medical need for these patients.
Treatment of this patient population with melphalan/PHP has been demonstrated to alter the
disease course, as evidenced by the consistent, statistically significant, and clinically meaningful
benefits seen with melphalan/PHP treatment across the tumor-related efficacy endpoints in the
pivotal Phase 3 study. The toxicities associated with melphalan/PHP treatment need to be viewed
within the context of the aggressive natural history of disease in these patients and the ability of
melphalan/PHP treatment to alter the disease course. The REMS is designed to maintain a
positive risk-benefit for melphalan/PHP treatment.
At last count, 18.9% of shares were short. The MMs may be continuously whacking the SP down to cover in small increments, hoping to finish covering without making it shoot up. Just a theory...
I wish I could sit with a real MM on days like today and have them interpret real time what the MMs are doing.
Hey those were my shares! LOL. Onward and upward CWRN!
I'm holding long term. This treatment is absolutely necessary right now. Even if there is a delay, it will be a game changer in treatment of addiction.
MMs appear to be strategically selling small lots to keep it down while they accumulate, IMO.
GOOD JOB ROCKET!!!!!!!! Your patience pays off.
The last one I sat through was HEB - seems they didn't finish their decision until after markets closed. I think about half the traders will bail before just to preserve capital in case of a neg vote, and the true believers will stay in. JMHO, of course.
Merk has nothing to do with Delcath. Not even remotely similar - Merck's is an antibody therapy for melanoma.
Check out the trailer for "Oxyana", a new documentary premiering at the Tribeca filmfest. It depicts the total devastation on whole towns of oxycontin addiction, and the lack of effective treatments for this horrible addiction.
May be the best argument for TTNP approval ever.
WOW! Great DD Rocket! Geotech is a nasty piece of work!
If CWRN wins, potential multimillion dollar settlement. Or a big out-of-court settlement. Stay tuned.....
Good presentation from J. Pingpank (Aug 28th -2012 , After NDA submission)-Must watch
It would be good for copper to collapse. Maybe the dimwit meth junkies would stop stealing copper wiring.
Somebody needed $2100.
Hi Grajekk - still here. A lot of us oldtimers are watching patiently, quietly.
Hi Roy - I am lurking today. After doing my taxes, decided my trading skills are too poor to trade real money. So I will watch you guys some more to learn from you.
Have a great and profitable day!
Regards - Jane
DCTH from the patient's perspective. Good story.
http://www.dailymail.co.uk/health/article-2258625/Cancer-Mega-chemo-kill-cancer--effects-Treatment-transform-prospects-desperately-ill-patients.html#ixzz2QkZKOAju
(found by IS_Candid on InvestorVillage)
I am thinking it is short covering. Review docs for ODAC will be posted soon. If they are enticing, MMs don't want to be caught short - will want to be holding some cheap shares. JMHO
Thanks for the meeting details Biomanbaba!
Presentation from physician at Jefferson hospital who has performed around 350 procedures for metastaticocular melanoma. (Thanks to IS Candid on InvestorVillage DCTH board for sharing this.)
http://www.hemonctodaymelanoma.com/program12/contents/pdfs/Friday/Fri_1650_Sato_Uveal_Melanoma_Biology_and_Therapy.pdf
Key points from presentation
• Uveal melanoma is the most common primary eye malignancy in adults.
• Local treatments such as radioactive plaque and enucleation control the growth of primary tumors.
• After successful local eye treatment, up to 50% of patients subsequently develop metastases, with the liver as the most common site (often the only site).
• Local control of liver metastases can potentially extend survival.
• Metastases are resistant to standard systemic chemotherapies and novel approaches such as targeted therapies should be explored.
http://www.jeffersonhospital.org/diseases-conditions/cancer-uveal-melanoma
Do you think it is related to today's nosedive? Not sure I follow what the shortsqueeze data is suggesting.
Are there any moves towards class action yet?
I think so too. Added some more at these fine sale prices!
They seem to be working hard to keep this down today.
Yup - volume before price!
Running like a Banshee now!
Welcome home Mr. Bob. Let's get the show back on the road!
Wow - been out all day. Looks like whole gang is here. Lot of activity for a "dead" stock.
Picked up some cheapies yesterday, averaged down. Paid off nicely already.
Interesting posts on InvestorVillage re very good early results for DCTH/Chemosat in Europe. I know you cannot believe everything you read on the intertubes, but this is worth a look.
I plan to add - this sounds good.